Wells Fargo maintains Septerna at Overweight, raises price target to $61 from $50

Septerna, Inc. (SEPN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Septerna Announces Selection of SEP-204 as Development Candidate for Graves’ Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, th

Septerna, Inc. (SEPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expec

Barclays raised its price target for DuPont de Nemours to $176 from $156, citing a 14.7% upside from the Nov 3 close. Other recent targets range from $145 to $162. Barclays maintains an Overweight rating.

Riot Platforms (RIOT) announced a 15-year lease with a leading AI lab for its Corsicana campus, totaling 910 MW. This deal, along with others, brings RIOT's contracted data center revenue to $3.8B. The company expects $2.2B in average annual net operating income. RIOT has reduced its Bitcoin holdings and repaid a $200M credit facility, ending Q3 with $950M in liquidity.

Morgan Stanley kept Duolingo at Equal-Weight but raised its price target to $145 from $140, suggesting a 13.3% upside from the Nov 3 close of $128. Recent analyst targets for Duolingo range from $120 to $165.

Morgan Stanley kept Clorox at Equal-Weight, raising its price target to $94 from $87. This is an 8% increase and aligns with Clorox's recent closing price of $93.80. Recent analyst targets for the company range from $80 to $99.